|
|
|
CVS Forecast
Recent CVS Price |
|
CVS Forecast Price |
$55.15 |
+59.04% |
$87.71 |
As of 2024-05-03
Recent CVS Analyst Ratings Breakdown |
|
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
Strong buy ratings: |
13 |
13 |
13 |
12 |
Buy ratings: |
3 |
3 |
3 |
3 |
Hold ratings: |
6 |
6 |
5 |
5 |
Sell ratings: |
0 |
0 |
0 |
0 |
Strong sell ratings: |
0 |
0 |
0 |
0 |
Average rating: |
1.66 |
1.66 |
1.6 |
1.63 |
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.
For the CVS Health Corporation forecast (traded under symbol CVS) for one year forward price target at the top of this page, we have presented the average CVS forecast for forward target price across the 21 analysts covering CVS, as reported in
data provided by Zacks Investment Research via Quandl.com.
Meanwhile, note that the
median CVS forecast price target (median being the middle where half of analysts had a higher CVS forecast and half had a lower CVS forecast, which is a different metric than the average or mean) was $87.0 as of 2024-05-03, while the
highest CVS forecast in the analyst group was $101.0, and the lowest CVS forecast in the analyst group was
$76.0, with a standard deviation of $6.907. Get the latest Zacks research report on CVS — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Name: |
CVS Health Corporation |
Stock buyback: |
CVS buyback |
Website: |
www.cvshealth.com |
Sector: |
Diagnostics |
Number of ETFs Holding CVS: |
108 (see which ones) |
Total Market Value Held by ETFs: |
$8,620,031,463.57 |
Total Market Capitalization: |
$70,863,000,000 |
% of Market Cap. Held by ETFs: |
12.16% |
|
|
|
|
Buy (3.07 out of 4)
38th percentile
|
PARTNER NEWS:Thu, May 2, 2:59 AM, Zacks
Company News for May 2, 2024 Companies In The News Are CVS, PFE, PPL, ADP.
Wed, May 1, 5:40 AM, Zacks
CVS Health (CVS) Misses Q1 Earnings and Revenue Estimates CVS Health (CVS) delivered earnings and revenue surprises of -22.49% and 0.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
|
|